Abstract
Background: The pregnancy pathology preeclampsia is still among the leading causes of maternal and perinatal morbidity and mortality. At the same time, its etiology is far from being identified and remains obscure in a number of facets.
A number of hypotheses have been developed to explain the altered interplay between placenta and mother leading to the clinical symptoms of preeclampsia. However, none of them offers the opportunity to explain the variability of cases with late-onset versus early-onset, mild versus severe and with or without additional fetal growth restriction.
Conclusion: This paper identifies the weaknesses of the most important current hypothesis and at the same time offers a set of new elucidations including maternal susceptibility, and villous/extravillous trophoblast differentiation to explain the development of preeclampsia. Such elucidations allow following new scientific routes and pathways to untangle the etiology of preeclampsia.
Keywords: Aponecrosis, extravillous trophoblast, fetal growth restriction, trophoblast invasion, placental oxygenation, preeclampsia, syncytiotrophoblast, villous trophoblast.
Graphical Abstract
Current Pharmaceutical Biotechnology
Title:The Critical Role of Abnormal Trophoblast Development in the Etiology of Preeclampsia
Volume: 19 Issue: 10
Author(s): Berthold Huppertz*
Affiliation:
- Department of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz,Austria
Keywords: Aponecrosis, extravillous trophoblast, fetal growth restriction, trophoblast invasion, placental oxygenation, preeclampsia, syncytiotrophoblast, villous trophoblast.
Abstract: Background: The pregnancy pathology preeclampsia is still among the leading causes of maternal and perinatal morbidity and mortality. At the same time, its etiology is far from being identified and remains obscure in a number of facets.
A number of hypotheses have been developed to explain the altered interplay between placenta and mother leading to the clinical symptoms of preeclampsia. However, none of them offers the opportunity to explain the variability of cases with late-onset versus early-onset, mild versus severe and with or without additional fetal growth restriction.
Conclusion: This paper identifies the weaknesses of the most important current hypothesis and at the same time offers a set of new elucidations including maternal susceptibility, and villous/extravillous trophoblast differentiation to explain the development of preeclampsia. Such elucidations allow following new scientific routes and pathways to untangle the etiology of preeclampsia.
Export Options
About this article
Cite this article as:
Huppertz Berthold *, The Critical Role of Abnormal Trophoblast Development in the Etiology of Preeclampsia, Current Pharmaceutical Biotechnology 2018; 19 (10) . https://dx.doi.org/10.2174/1389201019666180427110547
DOI https://dx.doi.org/10.2174/1389201019666180427110547 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preface (Hot Topic: Medicinal Strategies in the Treatment of Obesity Guest Editor: Akio Inui)
Current Medicinal Chemistry - Central Nervous System Agents Molecular Mechanisms of Several Novel Dipeptides with Angiotensin-Iconverting Enzyme Inhibitory Activity from In-silico Screening of Silkworm Pupae Protein
Current Pharmaceutical Biotechnology Reduction in Estimated Glomerular Filtration Rate (eGFR) Results in an Increased Risk of Spontaneous Hemorrhagic Transformation in Patients with Large-artery Atherosclerosis Stroke
Current Neurovascular Research Preeclampsia - Current Management and Future Approach
Current Pharmaceutical Biotechnology Platelet Activation in Alzheimer’s Disease: From Pathophysiology to Clinical Value
Current Vascular Pharmacology Treatment of Obesity: Should We Target the Individual or Society?
Current Pharmaceutical Design Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Editorial [ Hot topic:Metabolic Syndrome - Modern Pharmacological, Genetic, Clinical and Environmental Contributions (Guest Editor: Aldi T. Kraja)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Perspective Design of Chalcones for the Management of CNS Disorders: A Mini-Review
CNS & Neurological Disorders - Drug Targets Serelaxin: New Investigational Treatment in Acute Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry A Current Update on the Use of Alpha Lipoic Acid in the Management of Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Vasopressin and Oxytocin in Control of the Cardiovascular System
Current Neuropharmacology Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology Subclinical Vitamin B12 Deficiency and Heart Rate Variability Across Life Cycle
Current Aging Science Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design Leptin and Vascular Smooth Muscle
Current Vascular Pharmacology The Relevance of Dietary Polyphenols in Cardiovascular Protection
Current Pharmaceutical Design Estimation of Familial Combined Hyperlipoproteinemia Prevalence in a Large Rural Population: The Brisighella Heart Study
Vascular Disease Prevention (Discontinued) Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design The Importance of Novel Inflammatory Biomarkers in Renal Disease
Current Medicinal Chemistry